3//SEC Filing
MPM BIOVENTURES 2018, L.P. 3
Accession 0001209191-21-061991
CIK 0001689375other
Filed
Oct 27, 8:00 PM ET
Accepted
Oct 28, 8:47 PM ET
Size
10.9 KB
Accession
0001209191-21-061991
Insider Transaction Report
Form 3
MPM BioVentures 2018 LLC
10% Owner
Holdings
- (indirect: See Footnote)
Series A Preferred Stock
Exercise: $0.00→ Common Stock (3,816,760 underlying) - (indirect: See Footnote)
Series B Preferred Stock
Exercise: $0.00→ Common Stock (509,024 underlying)
MPM BIOVENTURES 2018, L.P.
10% Owner
Holdings
- (indirect: See Footnote)
Series B Preferred Stock
Exercise: $0.00→ Common Stock (509,024 underlying) - (indirect: See Footnote)
Series A Preferred Stock
Exercise: $0.00→ Common Stock (3,816,760 underlying)
MPM BioVentures 2018 GP LLC
10% Owner
Holdings
- (indirect: See Footnote)
Series A Preferred Stock
Exercise: $0.00→ Common Stock (3,816,760 underlying) - (indirect: See Footnote)
Series B Preferred Stock
Exercise: $0.00→ Common Stock (509,024 underlying)
Footnotes (4)
- [F1]Each share of Series A Preferred Stock and Series B Preferred Stock is convertible into shares of the Issuer's Common Stock on a 1:7.235890014 basis. Upon the closing of the Issuer's initial public offering, all shares of Series A Preferred Stock and Series B Preferred Stock will convert into shares of Common Stock of the Issuer. The Series A Preferred Stock and Series B Preferred Stock have no expiration dates.
- [F2]Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein.
- [F3]The shares are held as follows: 1,733,129 by MPM BioVentures 2014, L.P. ("BV 2014"), 115,596 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 59,655 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 1,778,737 by MPM BioVentures 2018, L.P. ("BV 2018"), 94,538 by MPM BioVentures 2018 (B), L.P. ("BV 2018(B)") and 35,105 by MPM Asset Management Investors BV2018 LLC ("AM BV2018"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV2014 LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV2014 LLC is the manager of AM BV2014. MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC ("BV2018 LLC") are the direct and indirect general partners of BV 2018 and BV 2018(B). BV 2018 LLC is the manager of AM BV2018. Messrs. Evnin and Gadicke are managing directors of BV 2014 LLC and BV 2018 LLC.
- [F4]The shares are held as follows: 231,139 by BV 2014, 15,417 by BV 2014(B), 7,956 by AM BV2014 LLC, 237,222 by BV 2018, 12,608 by BV 2018(B) and 4,682 by AM BV2018 LLC.
Documents
Issuer
Entrada Therapeutics, Inc.
CIK 0001689375
Entity typeother
IncorporatedDE
Related Parties
1- filerCIK 0001729505
Filing Metadata
- Form type
- 3
- Filed
- Oct 27, 8:00 PM ET
- Accepted
- Oct 28, 8:47 PM ET
- Size
- 10.9 KB